Effect of coadministration of AZD1152 and either vincristine or daunorubicin on the proliferation of MOLM13 cells in murine xenograft model. (A,D) MOLM13 cells were injected bilaterally subcutaneously into BALB/c nude mice, forming 2 tumors/mouse. When MOLM13 tumors were palpable, mice were randomized into 4 groups (n=5) and treatment was initiated. AZD1152 (5 mg/kg) was administered to mice by intraperitoneal injection 4 times a week for 2 weeks. VCR (0.2 mg/kg) was given every another day during the first week of therapy. DNR (1 mg/kg) was given to mice by intraperitoneal injection 6 times during 2 weeks of treatment. Tumor volumes were measured twice a week. Each point represents the mean ± SD of 10 tumors. (B,E) Tumor weights at autopsy. After 2 weeks of treatment, tumors were removed and weighed. Results represent mean plus or minus SD of tumor weights. Statistical significance was determined by one-way ANOVA followed by Bonferroni multiple comparison tests. Bars indicate SD. (C,F) Body weight. Body weight of mice was measured twice a week during treatment. AZD indicates AZD1152; VCR, vincristine; DNR, daunorubicin; and cont, diluent control.